GarnettCEBeasleyNBhattaramVA. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48:13–18.
2.
DarpoBBensonCDotaC. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther. 2015; 97:326–335.
3.
DarpoBGarnettC. Early QT assessment—how can our confidence in the data be improved?Br J Clin Pharmacol. 2013;76:642–648.
4.
WesterbergGChiesaJAAndersenCA. Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers. Br J Clin Pharmacol. 2015;79:477–491.
5.
ZhangJChenHTsongYStockbridgeN. Lessons learned from hundreds of thorough QT studies. Therapeutic Innovation & Regulatory Science. 2015;49:392–397.
